Mammary Cell News Volume 12.44 | Nov 12 2020

    0
    70







    2020-11-12 | MCN 12.44


    Mammary Cell News by STEMCELL Technologies
    Vol. 12.44 – 12 November, 2020
    TOP STORY

    CDK4/6 Inhibition Reprograms the Breast Cancer Enhancer Landscape by Stimulating AP-1 Transcriptional Activity

    Using cell-based and mouse models of breast cancer together with clinical specimens, scientists showed that CDK4/6 inhibitors induced remodeling of cancer cell chromatin characterized by widespread enhancer activation.
    [Nature Cancer]

    Abstract

    Scientific resources to support your cancer research. Learn More!
    PUBLICATIONSRanked by the impact factor of the journal

    Biomaterial-Based Scaffold for In Situ Chemo-Immunotherapy to Treat Poorly Immunogenic Tumors

    The authors describe a general strategy for in situ cancer vaccination that exploits both the immunogenic death of tumor cells and dendritic cell recruitment by biomaterial scaffolds. The strategy controlled 4T1 tumor growth and reduced metastases with minimal systemic toxicity, potentially providing a potent therapeutic option for TNBCs.
    [Nature Communications]

    Full ArticlePress Release

    Characterization of the Genomic Landscape and Actionable Mutations in Chinese Breast Cancers by Clinical Sequencing

    Researchers revealed that the most significant differences between Chinese and Western patients occurred in the hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer subtype.
    [Nature Communications]

    Full Article

    Systemic Delivery of NAC-1 siRNA by Neuropilin-Targeted Polymersomes Sensitizes Antiangiogenic Therapy of Metastatic Triple-Negative Breast Cancer

    Investigators found that neuropilin-1-targeted delivery of nucleus accumbens-associated protein-1 (NAC-1) siRNA mediated by tLyP-1 peptide-functionalized chimeric polymersomes effectively sensitized anti-angiogenic therapy of metastatic TNBC in vivo.
    [Biomacromolecules]

    AbstractGraphical Abstract

    Cold-Inducible RNA Binding Protein Promotes Breast Cancer Cell Malignancy by Regulating Cystatin C Levels

    The authors found that cold-inducible RNA binding protein (CIRBP) transcript levels correlated with breast cancer subtype and was an indicator of luminal A/B prognosis. Accordingly, over-expression of CIRBP in non-tumoral MCF-10A cells promoted cell growth and clonogenicity, while depletion of CIRBP from luminal A MCF-7 cells had the opposite effects.
    [RNA]

    Abstract

    Coffee Decoction Enhances Tamoxifen Proapoptotic Activity on MCF-7 Cells

    Scientists clarified how coffee decoction exerts anti-cancer effects in cooperation with tamoxifen using the estrogen receptor α-positive breast cancer cell line, MCF-7.
    [Scientific Reports]

    Full Article

    Tamoxifen Induces Hypercoagulation and Alterations in ERα and ERβ Dependent on Breast Cancer Sub-Phenotype Ex Vivo

    Researchers present two ex vivo models of tamoxifen-therapy, model one in which treatment recapitulated accumulation within breast tissue, by treating MCF7 and T47D cells directly prior to exposure to blood constituents; and model two in which they recreated circulating Tamoxifen by treating blood constituents prior to exposure to cancer cells.
    [Scientific Reports]

    Full Article

    Spliceosome-Associated MicroRNAs Signify Breast Cancer Cells and Portray Potential Novel Nuclear Targets

    Scientists studied human breast cancer-derived cell-lines and a non-tumorigenic cell-line and compared their miRNA sequences at the spliceosome fraction. They report that the levels of miRNAs found in the spliceosome, their identity, and pre-miRNA segmental composition were cell-line specific.
    [International Journal of Molecular Sciences]

    Full Article

    Endocytosis and Trafficking of Heparan Sulfate Proteoglycans in Triple-Negative Breast Cancer Cells Unraveled with a Polycationic Peptide

    Using NT4 as an experimental tool mimicking heparin-binding ligands, researchers studied endocytosis and trafficking of heparan sulfate proteoglycan in a human TNBC cell line, MDA-MB-231.
    [International Journal of Molecular Sciences]

    Full Article

    Connect with us via LiveChat to ask your scientific support questions
    REVIEWS

    Challenges and Achievements of Liquid Biopsy Technologies Employed in Early Breast Cancer

    The authors describe the recent progress in the utilization of the circulating tumor components using early breast cancer samples. They also review the most important analytes and technologies employed for the study.
    [Ebiomedicine]

    Full Article

    Breast Cancer Heterogeneity and Response to Novel Therapeutics

    Understanding the genetic variability and also the non-genetic influences of tumor heterogeneity will provide novel insights into how to reverse therapeutic resistance and improve cancer therapy
    [Cancers]

    Full ArticleGraphical Abstract

    INDUSTRY AND POLICY NEWS

    Therapeutic Solutions International Reports Augmentation of Immunotherapy Efficacy in Breast Cancer Model Utilizing Patented NanoStilbeneâ„¢ Nutraceutical Product

    Therapeutics Solution International, Inc. announced novel data supporting utilization of the company’s NanoStilbeneâ„¢ product for enhancement of cancer immunotherapy clinical trials.
    [Therapeutics Solution International, Inc. (PR Newswire Association, LLC.)]

    Press Release

    eFFECTOR Announces Dosing of First Breast Cancer Patient with Tomivosertib in Combination with Chemotherapy through a Grant from Stand Up To Cancer® (SU2C) Canada

    eFFECTOR Therapeutics, Inc. announced that the first breast cancer patient has been dosed with a combination of tomivosertib and paclitaxel in a Phase II study led by McGill University in Canada.
    [eFFECTOR Therapeutics, Inc. (Globe Newswire Inc.)]

    Press Release

    FEATURED EVENT

    Cell Symposia: 20 Years of the Human Genome: From Sequence to Substance

    April 11 – April 13, 2021
    San Diego, California, United States

    > See All Events

    JOB OPPORTUNITIES

    Senior Scientist – Tumor Biology

    Pfizer – La Jolla, California, United States

    Postdoctoral Research Fellow – Breast Cancer

    University of North Dakota – Grand Forks, North Dakota, United States

    Research Associate – Computational Breast Cancer

    Cancer Research UK Cambridge Institute – Cambridge, England, United Kingdom

    Senior Group Leader – Rare Cancers

    IRCCS Candiolo Cancer Institute – Candiolo, Italy

    Postdoctoral Position – Breast Cancer Computational Biology

    University of Oslo – Oslo, Norway

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Science News Mammary Cell News Archives Contact Us
    Mammary Cell News Twitter